20:57:10 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Spago Nanomedical är verksamma inom bioteknik. Bolaget utvecklar nanomedicin för diagnostik och behandling av livshotande sjukdomar. Bolagets huvudsakliga verksamhet är inriktad mot att utveckla ett cancerselektivt kontrastmedel för magnetisk resonanstomografi (MR), samt en produkt för radionuklidbehandling av cancer. Båda dessa projekt är baserade på egenutvecklade nanomaterial. Störst verksamhet återfinns inom den nordiska marknaden.

Kalender

2023-02-02 Bokslutskommuniké 2022
2022-11-08 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning SPAGO 0.00 SEK
2022-05-18 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-02 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning SPAGO 0.00 SEK
2021-05-05 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-02 Bokslutskommuniké 2020
2021-01-15 Extra Bolagsstämma 2021
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-24 Kvartalsrapport 2020-Q2
2020-05-29 Ordinarie utdelning SPAGO 0.00 SEK
2020-05-28 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-01-30 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-11-13 Extra Bolagsstämma 2019
2019-05-09 Ordinarie utdelning SPAGO 0.00 SEK
2019-05-08 Årsstämma 2019
2019-04-25 Kvartalsrapport 2019-Q1
2019-01-30 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-05-17 Ordinarie utdelning SPAGO 0.00 SEK
2018-05-16 Årsstämma 2018
2018-04-25 Kvartalsrapport 2018-Q1
2018-02-14 Bokslutskommuniké 2017
2017-11-08 Kvartalsrapport 2017-Q3
2017-09-22 Extra Bolagsstämma 2017
2017-08-25 Kvartalsrapport 2017-Q2
2017-05-18 Ordinarie utdelning SPAGO 0.00 SEK
2017-05-17 Årsstämma 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-14 Bokslutskommuniké 2016
2016-11-08 Kvartalsrapport 2016-Q3
2016-08-26 Kvartalsrapport 2016-Q2
2016-05-12 Ordinarie utdelning SPAGO 0.00 SEK
2016-05-11 Årsstämma 2016
2016-04-27 Kvartalsrapport 2016-Q1
2016-02-12 Bokslutskommuniké 2015
2015-11-12 Extra Bolagsstämma 2015
2015-11-06 Kvartalsrapport 2015-Q3
2015-08-27 Kvartalsrapport 2015-Q2
2015-05-06 Ordinarie utdelning SPAGO 0.00 SEK
2015-05-05 Årsstämma 2015
2015-04-29 Kvartalsrapport 2015-Q1
2015-02-20 Bokslutskommuniké 2014
2014-11-14 Kvartalsrapport 2014-Q3
2014-08-27 Kvartalsrapport 2014-Q2
2014-04-30 Ordinarie utdelning SPAGO 0.00 SEK
2014-04-29 Årsstämma 2014
2014-04-29 Extra Bolagsstämma 2014
2014-04-29 Kvartalsrapport 2014-Q1
2014-02-21 Bokslutskommuniké 2013
2013-10-29 Kvartalsrapport 2013-Q3
2013-08-29 Kvartalsrapport 2013-Q2
2013-05-24 Kvartalsrapport 2013-Q1
2013-04-25 Årsstämma 2013
2013-02-22 Bokslutskommuniké 2012

Prenumeration

2021-11-10 08:40:00

Tumorad® moves closer to clinical trials

JULY – SEPTEMBER IN BRIEF

  • Net sales for the quarter amounted to KSEK 195 (KSEK 67).
  • The loss for the quarter amounted to KSEK –10,103 (KSEK -4,485).
  • Operating expenses for the quarter amounted to KSEK -11,756 (KSEK -6,011).
  • Earnings per share, before and after dilution, for the quarter amounted to SEK -0.26 (SEK -0.14).
  • Cash and cash equivalents at the end of the quarter amounted to KSEK 65,987 (KSEK 35,699).

 JANUARY – SEPTEMBER IN BRIEF

  • Net sales for the year amounted to KSEK 561 (KSEK 167).
  • The loss for the year amounted to KSEK -27,778 (KSEK -14,304).
  • Operating expenses for the year amounted to KSEK -32,645 (KSEK -19,050).
  • Earnings per share, before and after dilution, for the year amounted to SEK -0.67 (SEK -0.56).

 SIGNIFICANT EVENTS DURING THE QUARTER

  • Paul Hargreaves was appointed Chief Development Officer (CDO). Paul will join the management team and have a key role in the clinical development of the company's project portfolio.

 SIGNIFICANT EVENTS AFTER THE QUARTER

  • Agreement was signed with the global CRO Cmed Group Limited for the development of the first clinical study with the company’s therapy projectTumoad.

CEO STATEMENT
We continue to make important progress in the projects and during the third quarter we were, not least, able to move Tumorad® closer to clinical studies. The development is proceeding according to plan, and the target is to start the first clinical trial with the candidate drug SN201 in patients with advanced cancer in 2022.
 
Recruitment for the clinical study SPAGOPIX-01 remains in focus. The target is to complete the current dose group as soon as possible and decide on the next step. The interim results communicated from the study so far show that SpagoPix (SN132D) clearly accumulates in cancerous tumors to provide images of tumors with high precision and positive contrast without disturbing background.
 
Our platform technology thus provides the opportunity to clinically and precisely accumulate functional nanoparticles in solid tumors. In a preclinical model for aggressive breast cancer, SN201 has shown a positive effect by delaying tumor growth. We thus believe that Tumorad can be an important and effective addition to the treatment arsenal and that SN201 has a great potential against aggressive and spread cancer, and have a place in the growing market for radionuclide-based cancer treatment.
 
There is currently a lack of effective drugs for advanced stages of several major cancers where mortality is largely due to the tumors continuing to grow or spread. Targeted radionuclide therapy as a treatment for spread cancer has attracted increasing interest in recent years with the development success of big pharma with Novartis in the lead. Already market-approved drugs, and not least completed partnering deals in the field, show that there is a significant value in the radionuclide therapy market. As an example, Coherent Market Insight estimates that the PRRT (Peptide Receptor Radionuclide Therapy) market will grow annually by 27 percent and be worth approximately $ 1.6 billion in 2027.
 
Paul Hargreaves recently joined Spago Nanomedical as Chief Development Officer, and the appointment of Paul, who has almost 30 years of experience in clinical development from Pfizer, among others, puts further focus on our important work. I am convinced that Paul will be a very valuable asset for our projects, especially in the work of preparing and implementing the clinical development with Tumorad.
 
We are well set to vigorously progress the projects.

Mats Hansen, CEO
Spago Nanomedical AB